MANZO, ALESSANDRO
MANZO, ALESSANDRO
Dipartimento di Biotecnologie Mediche e Medicina Traslazionale
The CHK1 inhibitor Prexasertib is effective against in vitro models of aggressive thyroid carcinomas with defective p53 function
2026 A. Manzo, E.S. Grassi, M.O. Borghi, C. Colombo, L. Persani, V. Cirello
TP53 Alterations Associate with Poor Response to Lenvatinib in Patients with Advanced Thyroid Cancer
2025 V. Cirello, C. Colombo, D. Tosi, A. Manzo, M.O. Borghi, U. Gianelli, G. Gazzano, S. Ferrero, G. Dionigi, L. Persani, L. Fugazzola
TARGETING THE DNA DAMAGE RESPONSE PATHWAY FOR THE TREATMENT OF AGGRESSIVE THYROID CANCERS, IN VITRO STUDIES
2024 A. Manzo
Thyroid cancer and endocrine disruptive chemicals: a case–control study on per-fluoroalkyl substances and other persistent organic pollutants
2024 V. Cirello, M. Lugaresi, C. Moneta, P. Dufour, A. Manzo, E. Carbone, C. Colombo, L. Fugazzola, C. Charlier, C. Pirard
Inactivating mutations of TP53 and resistence to tyrosine-kinase inhibitors in patients affected with aggressive thyroid cancer
2023 V. Cirello, C. Colombo, A. Manzo, D. Tosi, U. Gianelli, G. Gazzano, S. Ferrero, L. Persani, L. Fugazzola
Targeting the DNA damage response kinase CHK1 in TP53-mutated thyroid cancer: in vitro studies
2023 A. Manzo, V. Cirello, E.S. Grassi, C. Colombo, L. Fugazzola, L. Persani
Targeting the DNA damage response kinase Chk1 in TP53-mutated aggressive thyroid cancers: in vitro studies
2023 A. Manzo, V. Cirello, E.S. Grassi, C. Colombo, L. Fugazzola, L. Persani
Fetal cell microchimerism and susceptibility to COVID-19 disease in women
2023 V. Cirello, M. Lugaresi, A. Manzo, E. Balla, G. Fratianni, F. Solari, L. Persani, L. Fugazzola, I. Campi